2018 biopharma startup report

Details on $17B of VC investments and hundreds of investors.

In-depth coverage of $34B of venture-backed IPOs and $37B in venture-backed M&A.

Thousands of data points on 2018 IPOs: private round valuations, spend by R&D program, and more.

Get the complimentary 2018 summary report, and see options to access in-depth reports

Monitor the pulse of the industry

Will 2019 be a year of bounty or volatility? Look beyond the NASDAQ Biotech Index with our coverage of 2018 activity, including $17B in venture investment, venture-backed IPOs worth $34B, and $37B in venture-backed M&A.

Responsive image
Responsive image

See what's getting funded

Succinct descriptions of hundreds of startups that raised venture money in 2018.

Target your partnering and funding strategy

Quickly qualify leads. See who's leading Series A rounds, what companies are most likely to IPO in 2019, who's doing gene therapy partnerships, and more.

Responsive image
Responsive image

Know who's across the table

Digestible profiles of hundreds of startups and investors, including therapeutic areas and indications, cash proceeds and cash-on-cash returns for major investors in 2018 biopharma IPOs, 2018 deal activity and more.

See what drives value

Negotiate better deals with estimated private-round valuations for select companies. Benchmark your capital needs with data on historical R&D spend by research program for select companies.

Sign up to get the complimentary 2018 biopharma essentials report

and see options to access in-depth reports

Privacy policy

Terms of use

© 2019 Bay Bridge Bio, LLC